Aderbasib

Aderbasib is an investigational drug being developed for the treatment of fibrotic diseases, particularly those affecting the lungs. It is a selective inhibitor of the ALK5 (Activin receptor-like kinase 5) receptor, a key mediator in the TGF-β (Transforming Growth Factor-beta) signaling pathway. TGF-β signaling is implicated in the pathogenesis of fibrosis, a process characterized by excessive accumulation of extracellular matrix proteins, leading to tissue scarring and organ dysfunction.

By inhibiting ALK5, Aderbasib aims to reduce the downstream effects of TGF-β signaling, thereby mitigating the fibrotic process. Preclinical studies have suggested that Aderbasib may reduce collagen deposition and improve lung function in animal models of pulmonary fibrosis.

Clinical trials are ongoing to evaluate the safety and efficacy of Aderbasib in patients with idiopathic pulmonary fibrosis (IPF) and other fibrotic conditions. The therapeutic potential of Aderbasib lies in its ability to target a central pathway involved in fibrosis, offering a potential new treatment option for diseases with limited current therapies. The drug is administered orally.